By activating both GLP-1 and GIP receptors, they tend to produce greater effects on weight loss and metabolic health than single GLP-1 receptor agonists.
This occurred more frequently among Gen Z (28%) compared to millennials (18%) and Gen X (12%), and it happened about the same among men (19%) and women (18%)
Introducing Mounjaro: a dual-action approach Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors
Key takeaways Phentermine and Vyvanse are both central nervous system stimulant medications that affect dopamine and norepinephrine, but phentermine is an appetite suppressant for weight loss while Vyvanse is primarily for the treatment of ADHD and binge-eating disorders
GLP-1 related hair loss is most commonly telogen effluvium, which causes diffuse thinning across the entire scalp rather than the patterned thinning seen in androgenic alopecia (male or female pattern baldness)
Wegovy directly suppresses appetite as part of its therapeutic action, whilst bupropion may cause appetite changes as a secondary effect in some individuals
